Long-term results of splenectomy in adult chronic immune thrombocytopenia

European Journal of Haematology

Volumn 98, Issue 3, 2017, Pages 235-241

  Guan, Yue ^a   Wang, Shixuan ^a   Xue, Feng ^a   Liu, Xiaofan ^a   Zhang, Lei ^a   Li, Huiyuan ^a   Yang, Renchi ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

adult; chronic; immune thrombocytopenia; splenectomy

Indexed keywords

PREDNISONE; IMMUNOGLOBULIN;

ACCESSORY SPLEEN; ADOLESCENT; ADULT; AGED; APPENDICITIS; ARTICLE; BRAIN INFARCTION; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; EDEMA; FEMALE; FOLLOW UP; FURUNCULOSIS; HEART INFARCTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; PATIENT SAFETY; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SPLENECTOMY; SURGICAL INFECTION; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE; CHRONIC DISEASE; MIDDLE AGED; MORBIDITY; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TIME TO TREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MORBIDITY; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SPLENECTOMY; TIME-TO-TREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84998723883     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12821     Document Type: Article

References (45)

1. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009;113:6511–21.
2. Yang L, Wang L, Zhao CH, Zhu XJ, Hou Y, Jun P, Hou M. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood 2010;116:4307–16.
3. Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol 2013;98:24–33.
4. Yoshida Y. Historical review. The light and shadow of Paul Kaznelson: his life and contribution to hematology. Ann Hematol 2008;87:877–9.
5. Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther 2015;32:875–87.
6. Browning MG, Bullen N, Nokes T, Tucker K, Coleman M. The evolving indications for splenectomy. Br J Haematol 2016. doi:10.1111/bjh.14060.
7. Michel M, Suzan F, Adoue D, Bordessoule D, Marolleau JP, Viallard JF, Godeau B. Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012. Br J Haematol 2015;170:218–22.
8. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190–207.
9. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–86.
10. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012;120:960–9.
11. Sailer T, Lechner K, Panzer S, Kyrle PA, Pabinger I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006;91:1041–5.
12. Simanek R, Panzer S, Lechner K, Pabinger I. Late spontaneous remissions in severe adult autoimmune thrombocytopenia. Ann Hematol 2007;86:705–10.
13. Stasi R, Newland A, Thornton P, Pabinger I. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Ann Hematol 2010;89:1185–95.
14. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–93.
15. Vianelli N, Palandri F, Polverelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica 2013;98:875–80.
16. Patel NY, Chilsen AM, Mathiason MA, Kallies KJ, Bottner WA. Outcomes and complications after splenectomy for hematologic disorders. Am J Surg 2012;204:1014–20.
17. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013;121:4782–90.
18. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Jacobsen J, Fryzek JP, Sørensen HT. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med 2009;151:546–55.
19. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 2001;54:214–8.
20. Theilacker C, Ludewig K, Serr A, et al. Overwhelming postsplenectomy infection: a prospective multicenter cohort study. Clin Infect Dis 2016;62:871–8.
21. Kuchar E, Miśkiewicz K, Karlikowska M. A review of guidance on immunization in persons with defective or deficient splenic function. Br J Haematol 2015;171:683–94.
22. Edgren G, Almqvist R, Hartman M, Utter GH. Splenectomy and the risk of sepsis: a population-based cohort study. Ann Surg 2014;260:1081–7.
23. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AØ, Nørgaard M, Zhao S, Sørensen HT. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011;152:360–2.
24. Ruggeri M, Tosetto A, Palandri F, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost 2014;12:1266–73.
25. Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 2012;119:1356–62.
26. Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 2014;124:3228–36.
27. Patel VL, Mahe′vas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119:5989–95.
28. Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA; RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015;385:1653–61.
29. Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Derumeaux H, Adoue D. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. Am J Hematol 2014;89:41–6.
30. Rodeghiero F, Ruggeri M. Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists. Semin Hematol 2015;52:16–24.
31. Mahévas M, Gerfaud-Valentin M, Moulis G, et al. Characteristics, outcome and response to therapy of multirefractory chronic immune thrombocytopenia. Blood 2016;128:1625–30.
32. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889–99.
33. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537–45.
34. Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, Specchia G. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete EmatologicaPugliese (REP). Ann Hematol 2016;95:239–44.
35. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623–34.
36. Shojaiefard A, Mousavi SA, Faghihi SH, Abdollahzade S. Prediction of response to splenectomy in patients with idiopathic thrombocytopenic purpura. World J Surg 2008;32:488–93.
37. Aleem A. Durability and factors associated with long term response after splenectomy for primary immune thrombocytopenia (ITP) and outcome of relapsed or refractory patients. Platelets 2011;22:1–7.
38. Liu EH, Dilip CK, Yeh TS, Wu JH, Jan YY, Chen MF. Long-term relapse-free survival rate and predictive factors of idiopathic thrombocytopenic purpura in adults undergoing splenectomy. Biomed J 2013;36:23–7.
39. 111In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. Br J Haematol 2010;151:477–87.
40. Navez J, Hubert C, Gigot JF, Navez B, Lambert C, Jamar F, Danse E, Lannoy V, Jabbour N. Does the site of platelet sequestration predict the response to splenectomy in adult patients with immune thrombocytopenic purpura? Platelets 2015;26:573–6.
41. Park YH, Yi HG, Kim CS, et al. Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study. Acta Haematol 2016;135:162–71.
42. Vecchio R, Intagliata E, La Corte F, Marchese S, Cacciola RR, Cacciola E. Late results after splenectomy in adult idiopathic thrombocytopenic purpura. JSLS 2015;19:e2013.00272.
43. Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, Barbui T, Tura S, Baccaranion M; Gruppo Italiano per lo Studio delle Malattie Ematologiche dell'Adulto. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005;90:72–7.
44. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008;371:395–403.
45. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641–8.